Q-omics provides the consensus-scored VPS41 profile across patient tissues and cancer cell-line models. VPS41 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, VPS41 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, VPS41 RNA expression shows 19,870 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, HNSC, and THYM as cancer lineages where VPS41 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VPS41 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VPS41 survival associations across molecular data types. VPS41 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VPS41 RNA expression–survival associations across cancer types. High VPS41 expression shows unfavorable associations in BLCA, CESC, LGG and STAD, but favorable associations in KIRC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for VPS41 RNA expression.
This table summarizes VPS41 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for VPS41. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VPS41 shows higher tumor expression in HNSC, LIHC, KIRP, CHOL, COAD and STAD. The HNSC box plot shows higher VPS41 RNA expression in tumor versus normal tissue (log2 FC = +0.663, t-test p < 0.001).
This table shows molecular features associated with VPS41 in patient tissues and cancer cell lines. In patient samples, VPS41 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, VPS41 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
